Il 12 23 Inhibitor denied as experimental or investigational by Cigna?

Cigna requires prior authorization for ustekinumab (Stelara and biosimilars) and the same criteria apply across the IL-12/23 inhibitor class. The SC formulation is covered for Crohn's disease (CD), plaque psoriasis (PsO), psoriatic arthritis (PsA), and ulcerative colitis (UC), while the IV formulation is covered for CD and UC. Prior authorization is required for benefit coverage of ustekinumab intravenous, and approval is recommended only for those who meet the Criteria and Dosing for the listed indications. Initial therapy is approved for 6 months if criteria are met; continuation/re-authorization is approved for 1 year if the patient has been established on the drug for at least 3–6 months and continues to respond. The medication must be prescribed by or in consultation with a specialist in the condition being treated, and certain approvals are limited to 30 days when that is an adequate duration. Concurrent use with another biologic or with a targeted synthetic oral small molecule drug used for an inflammatory condition is not allowed because combination therapy is generally not recommended due to a potentially higher rate of adverse events and lack of controlled clinical data supporting additive efficacy , though conventional synthetic DMARDs (e.g., methotrexate, leflunomide, hydroxychloroquine, sulfasalazine) are not excluded. Through the Preferred Specialty Management program, the patient is required to meet the standard PA criteria and to try ALL of the Preferred Products prior to approval of a Non-Preferred Product. Pediatric dosing for PsA/PsO follows weight-based limits: pediatric patients ≥12 years weighing 60–100 kg receive 45 mg SC at Week 0, Week 4, then Q12W; those weighing <60 kg receive 90 mg SC at Week 0, Week 4, then Q12W.

- For step-therapy denials in IBD: AGA Clinical Guidelines on the Management of Moderate-to-Severe Ulcerative Colitis and Crohn's Disease support ustekinumab as a first-line biologic option, particularly in TNF-naïve patients; the UNITI-1, UNITI-2, IM-UNITI, and UNIFI pivotal trials demonstrated efficacy that does not require failure of every preferred product if medically inappropriate. - For psoriasis/PsA step-therapy denials: AAD-NPF Joint Guidelines (2019) and ACR/NPF PsA guidelines list ustekinumab as a recommended biologic; cite PHOENIX 1 & 2 (PsO) and PSUMMIT 1 & 2 (PsA) showing durable PASI 75 and ACR20 responses, supporting medical necessity when TNF inhibitors are contraindicated (e.g., demyelinating disease, CHF, latent TB risk). - For combination-therapy denials: cite that conventional synthetic DMARDs (methotrexate, leflunomide, hydroxychloroquine, sulfasalazine) are NOT excluded from concurrent use , so co-prescription with MTX should not trigger denial. - For specialist-prescriber denials: provide attestation from a rheumatologist/GI/derm or documented consult note, satisfying the requirement that the medication be prescribed by or in consultation with a specialist . - For non-FDA indication denials in AS/nr-axSpA: cite the TOPAS open-label study which showed 65% of patients (95% CI: 41%, 85%) achieved an ASAS40 response at Week 24 , supporting off-label medical necessity when ACR/SPARTAN-recommended TNFi and IL-17 options have failed or are contraindicated. - For continuation/reauthorization denials: submit objective response data (PASI improvement, Mayo/CDAI reduction, HBI, joint counts) showing the patient meets the established-therapy criterion of established on the requested drug for at least 3 months . - For non-preferred biosimilar denials on Employer/IFP plans: request a formulary exception citing significant allergy/intolerance to inactive ingredients in preferred products, per documentation supporting that formulation differences in inactive ingredients would result in a significant allergy .

## Why Cigna Denies an IL-12/23 Inhibitor as Experimental — and Why That Denial Is Appealable

A Cigna denial characterizing an IL-12/23 inhibitor as "experimental" or "investigational" warrants close scrutiny of the specific drug, indication, and Cigna's policy language. IL-12/23 inhibitors in current clinical use carry FDA approvals for specific indications including moderate-to-severe plaque psoriasis, psoriatic arthritis, and certain inflammatory bowel disease conditions. When an experimental denial is issued for an FDA-approved use, it is frequently an administrative or database error rather than a legitimate coverage determination.

However, if your prescription is for an off-label use — that is, a diagnosis or patient population not listed in the FDA-approved labeling — Cigna's experimental exclusion may have a different basis. In that situation, the appeal strategy shifts to demonstrating that the use is supported by substantial clinical evidence, referenced in a recognized medical compendia, and consistent with the applicable specialty society guideline.

## Your Federal Appeal Rights

• ACA §2719: Non-grandfathered plans must provide internal appeals and binding external review. External IRO reviewers apply objective clinical evidence standards and are not bound by Cigna's internal experimental-use determinations.
• ERISA §503: Employer plan members are entitled to a full-and-fair review, including access to the specific clinical criteria Cigna applied.
• Timeline: Internal appeal generally due within 180 days of denial. External review available for approximately four months after exhausting internal remedies. Use expedited review if delay poses a serious risk — for example, active severe Crohn's disease or rapidly progressing psoriatic arthritis.

## Documentation to Gather Before You Appeal

1. FDA approval status — identify the specific IL-12/23 inhibitor prescribed and confirm its FDA-approved indications. Download the official FDA drug-approval record and prescribing label. 2. On-label vs. off-label determination — confirm with your prescriber whether the use is FDA-approved or off-label. This determines the appeal strategy. 3. Diagnosis documentation — specialist notes confirming your diagnosis and how it maps to the labeled or evidence-supported indication. 4. Cigna's experimental-use policy — obtain Cigna's coverage policy for the specific drug and indication; confirm the criteria it uses to distinguish experimental from established use. 5. Prescriber letter — for on-label use: a letter citing the FDA approval. For off-label use: a letter citing the applicable specialty society guideline (by organization name, not specific statistics) and explaining why the use reflects established clinical practice. 6. Compendia listing — for off-label use, confirm whether the drug and indication appear in a recognized medical compendia accepted by Cigna's policy.

## Criteria-Mapping Structure

For an on-label denial: lead with the FDA approval record and state directly that the experimental exclusion does not apply. For an off-label denial: use a two-column table mapping each of Cigna's experimental-use criteria to the supporting clinical evidence. Cite guideline organization and compendia by name. Attach all exhibits and number them for easy reference.